Daniel Dicapua is a Neurology physician affiliated with Yale University. OpenAlex indexes 36 publications with 1,511 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARGENX US, INC.Program year20254 payments
- ARGENX US, INC.Program year202425 payments$25,569openpaymentsdata.cms.gov ↗
- Grifols USA, LLCProgram year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
67.7%Gabapentinoids43.1%Gabapentin53%Pregabalin47%Part D≥42 patientsBenzodiazepine7.4%Clonazepam51%Diazepam49%Part D<11 patients+ 6 more classes in this area
Musculoskeletal
21.7%gamma-Aminobutyric Acid-ergic Agonist11%Baclofen100%Part D≥15 patientsCentral alpha-2 Adrenergic Agonist5.2%Tizanidine Hcl100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
6.9%Corticosteroid6.9%Prednisone100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A novel discovery of elevated risk of neuroendocrine tumors in patients with myotonic dystrophy
Journal of the Neurological Sciences
2025 - HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): Case based discussion of risk factors, clinical, and therapeutic considerations
Journal of the Neurological Sciences
2024 - CMT2 and distal hereditary motor neuropathy associated with VRK1 variants: Case series
Neuromuscular Disorders
2024
Similar KOLs
Other experts from the same institution or the same specialty.
John Krystal, MD
Yale University
Lajos Pusztai, MD
Yale University
Lee Schwamm, MD
Yale University
Thomas McGlashan, MD
Yale University
Bruce Miller, MD
University of California, San Francisco (UCSF)
David Knopman, MD
Mayo Clinic Rochester
Brett Kissela, MD
Medical College of Wisconsin
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”